ID   OV-MZ-2
AC   CVCL_X951
DR   Wikidata; Q54936844
RX   DOI=10.5282/edoc.3898;
RX   PubMed=1500230;
RX   PubMed=15706405;
CC   Doubling time: 24 hours (PubMed=1500230).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 29-06-23; Version: 7
//
RX   DOI=10.5282/edoc.3898;
RA   Euer N.I.;
RT   "Identification of target genes for the therapy and diagnosis of
RT   ovarian carcinoma.";
RL   Thesis PhD (2005); Ludwig Maximilians University of Munich; Munich; Germany.
//
RX   PubMed=1500230; DOI=10.1002/ijc.2910520115;
RA   Mobus V.J., Gerharz C.-D., Press U., Moll R., Beck T., Mellin W.,
RA   Pollow K., Knapstein P.-G., Kreienberg R.;
RT   "Morphological, immunohistochemical and biochemical characterization
RT   of 6 newly established human ovarian carcinoma cell lines.";
RL   Int. J. Cancer 52:76-84(1992).
//
RX   PubMed=15706405; DOI=10.3892/or.13.3.375;
RA   Euer N.I., Kaul S., Deissler H., Mobus V.J., Zeillinger R.,
RA   Weidle U.H.;
RT   "Identification of L1CAM, Jagged2 and neuromedin U as ovarian
RT   cancer-associated antigens.";
RL   Oncol. Rep. 13:375-387(2005).
//